Tables will be used to summarise the relevant involvement of industries in developing safe and efficient cannabinoid-based medicines and, in particular, define the recent ongoing clinical tests focused on pain-related treatments
Weeks 8 through 16: appetite suppression at therapeutic levels As the dose climbs to 1.0 mg, 1.7 mg, and eventually 2.4 mg, the appetite suppression deepens
Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis
Vildagliptin was found to reduce fasting glucose, 4-h prandial glucose excursion and mean 24-hr glucose by 1 mmol/l and HbA1c by 0.4% (5 mmol/mol) after 4 weeks
Plasma trimethylamine N-oxide, a gut microbegenerated phosphatidylcholine metabolite, is associated with autism spectrum disorders